MDS 2022 | Management of iatrogenic hyperkinetic movement disorders

Carlo Colosimo, MD, FEAN, Santa Maria University Hospital, Terni, Italy, discusses the management of iatrogenic hyperkinetic movement disorders. In acute cases, when symptoms develop immediately after taking the drug, discontinuing the treatments involved as early as possible is the best strategy. The management of tardive syndromes is more challenging, but similarly to the acute cases, avoiding the treatments involved can be a potential approach; however, this is not always feasible as some patients can’t discontinue their treatments. In those cases, continuing treatment with a different drug that is less prone to cause tardive syndromes is a possibility. If those strategies are insufficient, some agents can be used to reduce tardive syndromes, particularly deutetrabenazine and valbenazine – both Food and Drug Administration (FDA)-approved. The drugs available to treat tardive syndromes in Europe include tetrabenazine, benzodiazepines, and botulinum toxin. In more severe cases, deep brain stimulation can be considered. This interview took place at the 2022 International Congress of Parkinson’s Disease and Movement Disorders in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.